User profiles for Owen R. Davies

Owen Davies

Senior Research Fellow, University of Edinburgh
Verified email at ed.ac.uk
Cited by 2529

Applications of supercritical CO2 in the fabrication of polymer systems for drug delivery and tissue engineering

OR Davies, AL Lewis, MJ Whitaker, H Tai… - Advanced drug delivery …, 2008 - Elsevier
Supercritical CO 2 has the potential to be an excellent environment within which controlled
release polymers and dry composites may be formed. The low temperature and dry …

Control of TSC2-Rheb signaling axis by arginine regulates mTORC1 activity

…, EA Dunlop, JF Passos, OR Davies, R Jaenisch… - Elife, 2016 - elifesciences.org
The mammalian target of rapamycin complex 1 (mTORC1) is the key signaling hub that
regulates cellular protein homeostasis, growth, and proliferation in health and disease. As a …

Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study

…, CO Bingham III, B Duncan, N Goel, OR Davies… - …, 2012 - academic.oup.com
Objective. To investigate the efficacy and safety of certolizumab pegol (CZP) in a broad
population of patients with active RA. Methods. In this 12-week, double-blind period of the phase …

Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID …

…, WP Maksymowych, OR Davies… - Annals of the …, 2018 - ard.bmj.com
Objectives To report 4-year imaging outcomes in the RAPID-axSpA ( NCT01087762 ) study
of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-…

Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial

…, W Samborski, F Berenbaum, OR Davies… - Annals of the …, 2015 - ard.bmj.com
Objectives This 52-week, randomised, double-blind phase IIIb study assessed efficacy and
safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying …

Crystal structure of human XLF/Cernunnos reveals unexpected differences from XRCC4 with implications for NHEJ

…, VM Bolanos‐Garcia, BL Sibanda, OR Davies… - The EMBO …, 2008 - embopress.org
The recently characterised 299‐residue human XLF/Cernunnos protein plays a crucial role
in DNA repair by non‐homologous end joining (NHEJ) and interacts with the XRCC4–DNA …

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction

…, K Gaffney, L Bauer, B Hoepken, OR Davies… - Annals of the …, 2020 - ard.bmj.com
Background The best strategy for maintaining clinical remission in patients with axial
spondyloarthritis (axSpA) has not been defined. C-OPTIMISE compared dose continuation, …

[HTML][HTML] C14ORF39/SIX6OS1 is a constituent of the synaptonemal complex and is essential for mouse fertility

…, M Sánchez-Martín, OR Davies… - Nature …, 2016 - nature.com
Meiotic recombination generates crossovers between homologous chromosomes that are
essential for genome haploidization. The synaptonemal complex is a ‘zipper’-like protein …

Structural basis of meiotic chromosome synapsis through SYCP1 self-assembly

…, C Millán, S Madgwick, I Uson, OR Davies - Nature structural & …, 2018 - nature.com
Meiotic chromosomes adopt unique structures in which linear arrays of chromatin loops are
bound together in homologous chromosome pairs by a supramolecular protein assembly, …

Meiotic chromosome structure, the synaptonemal complex, and infertility

IR Adams, OR Davies - Annual Review of Genomics and …, 2023 - annualreviews.org
In meiosis, homologous chromosome synapsis is mediated by a supramolecular protein
structure, the synaptonemal complex (SC), that assembles between homologous chromosome …